A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612.
Publication
, Journal Article
Assouline, S; Michaelis, LC; Othus, M; Hay, AE; Walter, RB; Jacoby, MA; Schroeder, MA; Uy, GL; Law, LY; Cheema, F; Sweet, KL; Asch, AS ...
Published in: Leukemia & lymphoma
February 2023
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Leukemia & lymphoma
DOI
EISSN
1029-2403
ISSN
1042-8194
Publication Date
February 2023
Volume
64
Issue
2
Start / End Page
473 / 477
Related Subject Headings
- Nivolumab
- Myelodysplastic Syndromes
- Middle Aged
- Leukemia, Myelomonocytic, Chronic
- Leukemia, Myeloid, Acute
- Immunology
- Humans
- Azacitidine
- 3201 Cardiovascular medicine and haematology
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Assouline, S., Michaelis, L. C., Othus, M., Hay, A. E., Walter, R. B., Jacoby, M. A., … Erba, H. P. (2023). A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612. Leukemia & Lymphoma, 64(2), 473–477. https://doi.org/10.1080/10428194.2022.2148212
Assouline, Sarit, Laura C. Michaelis, Megan Othus, Annette E. Hay, Roland B. Walter, Meagan A. Jacoby, Mark A. Schroeder, et al. “A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612.” Leukemia & Lymphoma 64, no. 2 (February 2023): 473–77. https://doi.org/10.1080/10428194.2022.2148212.
Assouline S, Michaelis LC, Othus M, Hay AE, Walter RB, Jacoby MA, et al. A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612. Leukemia & lymphoma. 2023 Feb;64(2):473–7.
Assouline, Sarit, et al. “A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612.” Leukemia & Lymphoma, vol. 64, no. 2, Feb. 2023, pp. 473–77. Epmc, doi:10.1080/10428194.2022.2148212.
Assouline S, Michaelis LC, Othus M, Hay AE, Walter RB, Jacoby MA, Schroeder MA, Uy GL, Law LY, Cheema F, Sweet KL, Asch AS, Liu JJ, Moseley AB, Maher T, Kingsbury LL, Fang M, Radich J, Little RF, Erba HP. A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612. Leukemia & lymphoma. 2023 Feb;64(2):473–477.
Published In
Leukemia & lymphoma
DOI
EISSN
1029-2403
ISSN
1042-8194
Publication Date
February 2023
Volume
64
Issue
2
Start / End Page
473 / 477
Related Subject Headings
- Nivolumab
- Myelodysplastic Syndromes
- Middle Aged
- Leukemia, Myelomonocytic, Chronic
- Leukemia, Myeloid, Acute
- Immunology
- Humans
- Azacitidine
- 3201 Cardiovascular medicine and haematology
- 1103 Clinical Sciences